key: cord-0297436-dr8h9mbq
authors: Pratedrat, P.; Nilyanimit, P.; Wasitthankasem, R.; Posuwan, N.; Hansoongnern, P.; Auphimai, C.; Pimsing, N.; Ngamnimit, S.; Thongmai, C.; Phaengkha, W.; Wanlapakorn, N.; Vongpunsawad, S.; Poovorawan, Y.
title: Qualitative hepatitis C virus RNA assay identifies active infection with sufficient viral load for treatment among Phetchabun residents in Thailand
date: 2022-05-11
journal: nan
DOI: 10.1101/2022.05.09.22274856
sha: f8958bf46fd3375df2da1b9b1b0d6fa1553c85b3
doc_id: 297436
cord_uid: dr8h9mbq

The World Health Organization envisions the elimination of viral hepatitis by 2030 through reducing prevalence and transmission, increasing diagnostic screening, and expanding treatment coverage. Efforts to micro-eliminate hepatitis in Phetchabun province in Thailand, a region where the prevalence of hepatitis C virus (HCV) infection and liver cancer is higher than elsewhere in the country, began with evaluating the province-wide burden of HCV. Here, we describe a feasibility study to assess active HCV infection by screening Phetchabun residents ages 35 to 69 years for anti-HCV antibodies by using a rapid diagnostic test (RDT) at the point of care. Positive anti-HCV results were further evaluated for active infection using qualitative HCV RNA assay, followed by quantitative HCV viral load determination in a subset of samples. Currently, we have identified 6.2% (10,621/170,163) anti-HCV positive individuals, of whom 74.9% (3,930/5,246) demonstrated detectable viral RNA. Quantitative test found that 97.5% (1,001/1,027) had HCV viral load >=5,000 IU/mL. Thus, primary screening with anti-HCV RDT followed by qualitative HCV RNA evaluation could identify active and chronic HCV infection in almost all individuals with a viral load >=5,000 IU/mL, which is the current threshold for the National Health Security Office treatment in Thailand. Our data suggest that qualitative HCV RNA evaluation may obviate the need for the more expensive quantitative HCV viral load test and reduce a significant barrier toward HCV elimination in a middle-income country.

in almost all individuals with a viral load ≥5,000 IU/mL, which is the current threshold for the 36 National Health Security Office treatment in Thailand. Our data suggest that qualitative HCV 37 RNA evaluation may obviate the need for the more expensive quantitative HCV viral load test 38 and reduce a significant barrier toward HCV elimination in a middle-income country.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Introduction 40 Globally, the hepatitis C virus (HCV) is a significant blood-borne pathogen, with chronic 41 infection being the leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) [ Georgia, and Mongolia are also expected to attain viral hepatitis elimination.

Although Thailand has a low national HCV seroprevalence (approximately 1%), 60 Phetchabun province reportedly has a higher rate of pre-existing HCV infection than the rest of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2022. ; https://doi.org/10.1101/2022.05.09.22274856 doi: medRxiv preprint the country [14] . Although the overall anti-HCV prevalence there is 6.9% according to the latest 62 study, the rate can vary in the north (10.8%) and south (2.9%) [15] . Due to its substantial HCV 63 burden, an HCV micro-elimination feasibility study was undertaken in Phetchabun. However, a 64 major obstacle to eliminating HCV in Thailand is the onerous preconditions necessary to access 65 government-subsidized HCV treatment. In addition to positive antibody status, additional 66 requirements include quantitative HCV RNA viral load ≥5,000 IU/mL and liver elastography or 67 hepatic marker panel assay evaluation by a physician specialist. These out-of-pocket costs often 68 deter patients with active hepatitis C from seeking timely medical attention and treatment.

Our previous study has shown that the anti-HCV rapid diagnostic test (RDT) is . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 1) , and quantitative HCV RNA viral load test on a subset of samples performed at a 96 specialized laboratory in Bangkok.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2022. ; https://doi.org/10.1101/2022.05.09.22274856 doi: medRxiv preprint

According to the manufacturer's instructions, finger-pricked whole blood (~10 μl) was 99 mixed with the kit solution and tested with the Anti-HCV RDT (SD Bioline HCV, Abbott, North 100 Chicago, IL). This RDT is a WHO pre-qualified rapid chromatographic immunoassay for the 101 qualitative HCV evaluation within 5-20 minutes.

Qualitative HCV RNA assay 103 Residents who tested positive for anti-HCV were referred to one of the three regional 104 hospitals where blood plasma was collected. Staff at these hospitals performed the qualitative . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2022. ; https://doi.org/10.1101/2022.05.09.22274856 doi: medRxiv preprint

Screening for anti-HCV using RDT 127 The prevalence of anti-HCV in 170,163 Phetchabun residents screened with RDT 128 represents 52.6% coverage of the eventual target population (Fig 1) . Of these, 10,621 tested 129 positive for RDT (6.2%) ( Table 2) There was no detectable HCV RNA in the remaining 7 samples (0.7%), possibly due to the 142 higher threshold limit of detection for this test than the qualitative assay.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In summary, a revised practical guideline incorporating cost-effectiveness and a 211 meaningful test-to-treat plan can help countries such as Thailand achieve HCV elimination by . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Locations of three regional hospitals performing the qualitative HCV RNA tests are marked.

Color-coded anti-HCV seropositivity identified thus far are indicated for each district. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2022. ; https://doi.org/10.1101/2022.05.09.22274856 doi: medRxiv preprint

Epidemiology of hepatitis C virus infection

Diagnosis and management of hepatitis C

Epidemiology of hepatitis C: geographic differences and temporal trends

Global prevalence and genotype distribution of hepatitis C virus 236 infection in 2015: a modelling study

Decreasing hepatitis C virus infection

Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward 263 HCV Elimination

Assessment 267 of hepatitis C virus infection in two adjacent Thai provinces with drastically different 268 seroprevalence

Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of 271 hepatitis C virus infection in 2015: a modelling study

Test Followed by a Confirmatory Qualitative Nucleic Acid Test Can Simplify Hepatitis C 276

Prospective study of risk 278 factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients

Chronic hepatitis C virus infection in the United States, National Health and Nutrition 282 Examination Survey

Markers and risk factors for 284

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2022. ; https://doi.org/10.1101/2022.05.09.22274856 doi: medRxiv preprint